Aspire Biopharma Files Patent For Sublingual Powder Formulation Of Clopidogrel And Methods Of Use Thereof

New sublingual delivery system designed to enhance bioavailability and avoid gastric side effects many patients experience with clopidogrel.

Clopidogrel, currently sold under the brand name Plavix®, was the 41st most commonly prescribed medication in the United States, with more than 15.2 million combined branded and generic prescriptions in 2023

ESTERO, FL / ACCESS Newswire / January 27, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted patent-pending drug delivery technology, today announced the filing of a new provisional patent application with the United States Patent and Trademark Office (USPTO). The application, titled "A Sublingual Powder Formulation of Clopidogrel and Methods of Use Thereof," covers the first-ever sublingual formulation of clopidogrel, the active pharmaceutical ingredient (API) in the widely prescribed blood thinner Plavix®.

This development represents a series of sublingual-based therapeutic alternatives the Company intends to commercialize via the FDA's 505(b)(2) regulatory pathway. Aspire's strategic pipeline focuses on reformulating approved generic therapeutics to address unmet needs where no sublingual alternatives currently exist, thus bringing the benefits of reducing or eliminating gastric irritation to products with these known side effects.